Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First RemissionAlexandre Bazinet, Tapan M. Kadia, Courtney D. DiNardo et al.|Blood|2024Cited by 4